Abstract: A pharmaceutical composition for an ophthalmic use either in humans or mammalians for a treatment of eye disorders is provided. The pharmaceutical composition includes an effective amount of an oxidizing agent and an effective amount of a photo-sensitizing agent, in combination with pharmaceutically acceptable excipients; the photo-sensitizing agent is a molecule having an absorbance peak in a wavelength range between 340 nm and 440 nm and emits fluorescence in a wavelength range between 450 nm and 600 nm; the oxidizing agent is chosen among molecules, wherein the molecules partially or totally inhibit a mitochondrial electron transport chain activity, wherein the pharmaceutical composition is a liquid formulation further includes one or more substances chosen among: diluents, permeabilizers, disinfectants, buffer systems, salts, antiseptics, and the pharmaceutically acceptable excipients.

Abstract: Control apparatus (1) for controlling the dosing of a chromophoric agent (100) in a corneal tissue (101), comprising: a first source (2) for irradiating the corneal tissue (101) with at least a first electromagnetic radiation (21); first measurement means (3) for measuring a first spectroscopic parameter (31), such as the fluorescence intensity or the diffused intensity; a processing unit (4) configured to calculate a factor (C) representative of the concentration of the chromophoric agent (100) inside the corneal tissue (101) in response to at least two measurements of the first spectroscopic parameter (31), of which one measurement is indicative of the energy perturbation caused by the first electromagnetic radiation (21) in the corneal tissue (101) without the chromophoric agent (100) and the further measurement is indicative of the energy perturbation caused by the first electromagnetic radiation (21) in the corneal tissue (101) containing the chromophoric agent (100).

Abstract: A device for delivering a drug into a cornea is provided. The device includes a body having an internal cavity and a first aperture communicating with the internal cavity, wherein the first aperture is conformed to hermetically adhere to a periphery of a surface of the cornea; a second aperture to introduce the drug in the internal cavity, the device further includes a mask, supported by the body in correspondence of the first aperture, wherein, in operative condition, the first aperture adheres to a portion of the surface of the cornea, and the mask includes a plurality of through openings of opportunely variable size to achieve a corresponding variable spatial concentration of the drug across the cornea.

Abstract: Control apparatus (1) for controlling the dosing of a chromophoric agent (100) in a corneal tissue (101), comprising: a first source (2) for irradiating the corneal tissue (101) with at least a first electromagnetic radiation (21); first measurement means (3) for measuring a first spectroscopic parameter (31), such as the fluorescence intensity or the diffused intensity; a processing unit (4) configured to calculate a factor (C) representative of the concentration of the chromophoric agent (100) inside the corneal tissue (101) in response to at least two measurements of the first spectroscopic parameter (31), of which one measurement is indicative of the energy perturbation caused by the first electromagnetic radiation (21) in the corneal tissue (101) without the chromophoric agent (100) and the further measurement is indicative of the energy perturbation caused by the first electromagnetic radiation (21) in the corneal tissue (101) containing the chromophoric agent (100).